Scott Rodig

Scott Rodig

UNVERIFIED PROFILE

Are you Scott Rodig?   Register this Author

Register author
Scott Rodig

Scott Rodig

Publications by authors named "Scott Rodig"

Are you Scott Rodig?   Register this Author

100Publications

4834Reads

15Profile Views

Overview of Tissue Imaging Methods.

Methods Mol Biol 2020 ;2055:455-465

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9773-2_21DOI Listing
January 2020

Detecting Gold-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Jul 1;2019(7):pdb.prot099754. Epub 2019 Jul 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099754DOI Listing
July 2019

Detecting Iodine-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Jul 1;2019(7):pdb.prot099762. Epub 2019 Jul 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099762DOI Listing
July 2019

Disruption of results in myeloproliferative neoplasms in zebrafish.

Dis Model Mech 2019 05 7;12(5). Epub 2019 May 7.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts 02215, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.035790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550042PMC
May 2019

Detecting Horseradish Peroxidase-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 04 1;2019(4). Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099713DOI Listing
April 2019

Detecting Alkaline Phosphatase-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 04 1;2019(4). Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099721DOI Listing
April 2019

Counterstaining, Mounting, and Photographing Stained Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 04 1;2019(4). Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099770DOI Listing
April 2019

Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.

Haematologica 2018 10 21;103(10):1679-1687. Epub 2018 Jun 21.

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.183236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165815PMC
October 2018

A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens.

Cytometry B Clin Cytom 2018 09 1;94(5):637-643. Epub 2018 Apr 1.

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21634DOI Listing
September 2018

Reply to Z. Wu et al.

J Clin Oncol 2018 09 30;36(25):2657. Epub 2018 May 30.

Donna S. Neuberg, Dana-Farber Cancer Institute; and Harvard T.H. Chan School of Public Health, Boston, MA; Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9826
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9826DOI Listing
September 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.

Oncoimmunology 2018 13;7(7):e1440930. Epub 2018 Mar 13.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1440930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993498PMC
March 2018

Implications of the tumor immune microenvironment for staging and therapeutics.

Mod Pathol 2018 02 1;31(2):214-234. Epub 2017 Dec 1.

Department of Pathology, The Johns Hopkins University SOM and Bloomberg-Kimmel Institute for Immunotherapy, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2017.156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132263PMC
February 2018

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Blood Adv 2017 Dec 12;1(26):2643-2654. Epub 2017 Dec 12.

Department of Pathology, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017012534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728646PMC
December 2017

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

J Clin Oncol 2017 Jun 13;35(16):1836-1844. Epub 2017 Apr 13.

Tsuyoshi Hamada, Zhi Rong Qian, Yohei Masugi, Juhong Yang, Kosuke Mima, Keisuke Kosumi, Li Liu, Yan Shi, Annacarolina da Silva, Mancang Gu, Wanwan Li, Jeffrey A. Meyerhardt, Marios Giannakis, Scott J. Rodig, Gordon J. Freeman, Charles S. Fuchs, Reiko Nishihara, and Shuji Ogino, Dana-Farber Cancer Institute and Harvard Medical School; Yin Cao, Mingyang Song, and Andrew T. Chan, Massachusetts General Hospital and Harvard Medical School; Yin Cao, Mingyang Song, Li Liu, NaNa Keum, Kana Wu, Edward L. Giovannucci, Daniel Nevo, Molin Wang, Reiko Nishihara, and Shuji Ogino, Harvard T.H. Chan School of Public Health; Jonathan A. Nowak, Xuehong Zhang, Edward L. Giovannucci, Marios Giannakis, Gordon J. Freeman, Molin Wang, Andrew T. Chan, Charles S. Fuchs, and Shuji Ogino, Brigham and Women's Hospital and Harvard Medical School, Boston; Marios Giannakis and Andrew T. Chan, Broad Institute of MIT and Harvard University, Cambridge, MA; Li Liu, Huazhong University of Science and Technology, Wuhan; Yan Shi, Chinese People's Liberation Army General Hospital, Beijing; and Mancang Gu, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455595PMC
June 2017

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Lab Invest 2017 02 5;97(2):207-216. Epub 2016 Dec 5.

Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.2016.126DOI Listing
February 2017

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.

Cell Stem Cell 2017 02 15;20(2):233-246.e7. Epub 2016 Dec 15.

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2016.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291795PMC
February 2017

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity 2017 02;46(2):197-204

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2017.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320PMC
February 2017

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

J Clin Oncol 2017 Jan 24;35(1):24-31. Epub 2016 Oct 24.

Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, David M. Weinstock, Scott J. Rodig, Philippe Armand, Dana-Farber Cancer Institute; Gabriel K. Griffin, Reid W. Merryman, Christine Pak, Heather Sun, Brigham and Women's Hospital; German A. Pihan, Beth Israel Deaconess Medical Center; and Aliyah R. Sohani, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455688PMC
January 2017

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Cancer Med 2016 11 17;5(11):3041-3050. Epub 2016 Oct 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119958PMC
November 2016

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.

Cancer Immunol Res 2016 10 22;4(10):858-868. Epub 2016 Aug 22.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050160PMC
http://dx.doi.org/10.1158/2326-6066.CIR-16-0084DOI Listing
October 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

J Clin Oncol 2016 08 6;34(23):2698-704. Epub 2016 Jun 6.

Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer Institute, Portland, OR; Ahmad Halwani, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Martin Gutierrez, Hackensack University Medical Center, Hackensack; Lili Zhu, Joseph F. Grosso, and M. Brigid Bradley Garelik, Bristol-Myers Squibb, Princeton, NJ; Michael M. Millenson, Fox Chase Cancer Center; Adam D. Cohen and Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; Daniel Lebovic, University of Michigan, Ann Arbor, MI; Madhav Dhodapkar, Yale Cancer Center, New Haven, CT; Ivan Borrello, Johns Hopkins University School of Medicine, Baltimore, MD; and John Timmerman, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019749PMC
August 2016

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Cancer Immunol Res 2016 08 16;4(8):679-87. Epub 2016 Jun 16.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0031DOI Listing
August 2016

Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.

Genome Biol 2016 08 22;17(1):174. Epub 2016 Aug 22.

Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13059-016-1028-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993001PMC
August 2016

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

N Engl J Med 2016 Jul;375(2):143-53

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1601202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149459PMC
July 2016

RelA-Induced Interferon Response Negatively Regulates Proliferation.

PLoS One 2015 13;10(10):e0140243. Epub 2015 Oct 13.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140243PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604146PMC
June 2016

The Role of Surgical Pathology in Guiding Cancer Immunotherapy.

Annu Rev Pathol 2016 05;11:313-41

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pathol-012615-044125DOI Listing
May 2016

Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.

Am J Surg Pathol 2016 Apr;40(4):443-53

*Department of Pathology, Brigham and Women's Hospital Departments of †Medical Oncology ‡Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000590DOI Listing
April 2016

MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.

Am J Clin Pathol 2016 Feb 1;145(2):166-79. Epub 2016 Feb 1.

From the Department of Pathology, Brigham and Women's Hospital, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqv028DOI Listing
February 2016

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1726-35

*Department of Medical Oncology, †Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; §Harvard Medical School, Boston, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. ¶Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and #Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000687DOI Listing
December 2015

Duration of symptoms does not correlate with results of T-cell gene rearrangement studies in patients evaluated for cutaneous T-cell lymphoma.

J Cutan Pathol 2015 Sep 29;42(9):618-21. Epub 2015 May 29.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12516DOI Listing
September 2015